REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
13/07/2026
Voltar para busca
Dado oficial do USPTO
ALLERGAN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
13/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
03/01/2018
Data de registro
13/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/07/2021
Última transação
13/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
30/06/2017
Primeiro uso no comércio
30/06/2017
Código do desenho
4
Tipo de titular
16
Localização do titular
Madison, NJ, US
Examinador
CLARK, ROBERT C
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Allergan Sales, LLC
Representantes
Matthew O. Brady AbbVie Inc.
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
House mark used for a line of pharmaceuticals used in connection with anti-agingthe treatment of glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfacial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetics; topical antibioticsanti-inflammatoryanti-infectiveanti-glaucoma and decongestant formulationspharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutionseye dropsartificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disordersmuscle dystoniassmooth muscle disordersautonomic nerve disordersheadacheshyperhydrosissports injuriescerebral palsyspasmstremors and pain; dermatological formulationsmedicated dry skin lotions and creamsacne medications and medicated skin lighteners; Oraltransdermalinjectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiacentral nervous system disordersneurological disordersneurodegenerative disordersdepressionneuroprotective agent; antidepressants; pharmaceuticalsantipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticalsmedicated skin cleanserstonersmoisturizersrejuvenatorsrehydrating creamslotions for the face and body; medicated cosmetic skin care preparations
Classe 10
House mark used for a line of surgicalmedicaldental and veterinary apparatus and instrumentsdiagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfor use in facial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetics and ophthalmic related diseases and disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/07/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/07/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/07/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/07/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
13/07/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/06/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/06/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/06/2021
IUAF
USE AMENDMENT FILED
04/06/2021
EISU
TEAS STATEMENT OF USE RECEIVED
04/06/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
30/12/2020
EX5G
SOU EXTENSION 5 GRANTED
29/12/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
29/12/2020
EXT5
SOU EXTENSION 5 FILED
10/12/2020
EEXT
SOU TEAS EXTENSION RECEIVED
10/12/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
16/06/2020
EX4G
SOU EXTENSION 4 GRANTED
12/06/2020
EXT4
SOU EXTENSION 4 FILED
12/06/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/06/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/12/2019
EX3G
SOU EXTENSION 3 GRANTED
06/12/2019
EXT3
SOU EXTENSION 3 FILED
06/12/2019
EEXT
SOU TEAS EXTENSION RECEIVED
06/12/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
14/06/2019
EX2G
SOU EXTENSION 2 GRANTED
12/06/2019
EXT2
SOU EXTENSION 2 FILED
12/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/12/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/11/2018
EX1G
SOU EXTENSION 1 GRANTED
29/11/2018
EXT1
SOU EXTENSION 1 FILED
29/11/2018
EEXT
SOU TEAS EXTENSION RECEIVED
29/11/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/06/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/04/2018
PUBO
PUBLISHED FOR OPPOSITION
17/04/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/03/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/03/2018
DOCK
ASSIGNED TO EXAMINER
13/03/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/01/2018
NWAP
NEW APPLICATION ENTERED
06/01/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ALLERGAN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.